Outset Medical (NASDAQ:OM) Issues Quarterly Earnings Results

Outset Medical (NASDAQ:OM) issued its earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04), Zacks reports. Outset Medical had a negative return on equity of 164.92% and a negative net margin of 122.84%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Price Performance

Shares of OM traded up $0.03 during trading hours on Wednesday, reaching $0.94. 1,529,358 shares of the company’s stock traded hands, compared to its average volume of 1,386,158. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12. Outset Medical has a 12 month low of $0.44 and a 12 month high of $5.22. The stock has a market cap of $50.48 million, a PE ratio of -0.34 and a beta of 2.01. The firm’s 50 day simple moving average is $0.96 and its 200-day simple moving average is $0.85.

Insider Transactions at Outset Medical

In other news, CFO Nabeel Ahmed sold 34,288 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total transaction of $27,430.40. Following the transaction, the chief financial officer now directly owns 258,869 shares of the company’s stock, valued at approximately $207,095.20. This trade represents a 11.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Leslie Trigg sold 33,227 shares of Outset Medical stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $0.81, for a total value of $26,913.87. Following the completion of the transaction, the chief executive officer now directly owns 861,397 shares in the company, valued at $697,731.57. This trade represents a 3.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 267,790 shares of company stock valued at $222,243 in the last quarter. Insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $3.00 target price on shares of Outset Medical in a report on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.